Recent News

• 07.30.2026 - FocalTherics™ to Announce Second Quarter 2026 Financial Results on August 13, 2026
• 06.30.2026 - FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients
• 06.16.2026 - FocalTherics™ Expands Access to Focal One® Robotic HIFU for Veterans with Prostate Cancer through Agreement with MellingMedical
• 05.29.2026 - EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy
• 05.21.2026 - EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference
• 05.14.2026 - EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer
• 05.13.2026 - EDAP | Focal One to Host Investor Day on June 1, 2026
• 05.07.2026 - EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue
• 04.30.2026 - EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One® Robotic HIFU in Radiorecurrent Prostate Cancer
• 04.16.2026 - EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026

Recent Filings

• 06.26.2026 - 8-K Current report
• 06.01.2026 - 8-K Current report
• 06.01.2026 - EX-99.1 EX-99.1
• 05.29.2026 - 8-K Current report
• 05.29.2026 - EX-99.1 EX-99.1
• 05.14.2026 - ARS Annual Report to Security Holders
• 05.14.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.14.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.14.2026 - DEF 14A Other definitive proxy statements
• 05.13.2026 - 4 Statement of changes in beneficial ownership of securities